Although GW5074 and sorafenib are both Raf inhibitors, their use in combination provides a novel mechanism of anti-tumor activity targeting cancer cell necroptosis induced by mitochondrial dysfunction, which is distinct from current Raf inhibitor therapies. Here, RAF1 is linked to neoplasm.